PL365588A1 - Stosowanie pochodnych amidów kwasu walproinowego i kwasu 2-walproenowego w leczeniu stanu pobudzenia maniakalnego w zaburzeniu charakteryzującym się epizodami depresyjnymi i maniakalnymi - Google Patents

Stosowanie pochodnych amidów kwasu walproinowego i kwasu 2-walproenowego w leczeniu stanu pobudzenia maniakalnego w zaburzeniu charakteryzującym się epizodami depresyjnymi i maniakalnymi

Info

Publication number
PL365588A1
PL365588A1 PL01365588A PL36558801A PL365588A1 PL 365588 A1 PL365588 A1 PL 365588A1 PL 01365588 A PL01365588 A PL 01365588A PL 36558801 A PL36558801 A PL 36558801A PL 365588 A1 PL365588 A1 PL 365588A1
Authority
PL
Poland
Prior art keywords
mania
derivatives
treatment
bipolar disorder
valproenic
Prior art date
Application number
PL01365588A
Other languages
English (en)
Inventor
Mitchel Shirvan
Meir Bialer
Original Assignee
Teva Pharmaceutical Industries, Ltd.
Yissum Research Development Company Of The Hebrewuniversity Of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries, Ltd., Yissum Research Development Company Of The Hebrewuniversity Of Jerusalem filed Critical Teva Pharmaceutical Industries, Ltd.
Publication of PL365588A1 publication Critical patent/PL365588A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL01365588A 2000-07-21 2001-07-20 Stosowanie pochodnych amidów kwasu walproinowego i kwasu 2-walproenowego w leczeniu stanu pobudzenia maniakalnego w zaburzeniu charakteryzującym się epizodami depresyjnymi i maniakalnymi PL365588A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22010200P 2000-07-21 2000-07-21

Publications (1)

Publication Number Publication Date
PL365588A1 true PL365588A1 (pl) 2005-01-10

Family

ID=22822065

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365588A PL365588A1 (pl) 2000-07-21 2001-07-20 Stosowanie pochodnych amidów kwasu walproinowego i kwasu 2-walproenowego w leczeniu stanu pobudzenia maniakalnego w zaburzeniu charakteryzującym się epizodami depresyjnymi i maniakalnymi

Country Status (16)

Country Link
US (2) US6555585B2 (pl)
EP (1) EP1303289A4 (pl)
JP (1) JP2004520263A (pl)
KR (1) KR100843703B1 (pl)
CN (1) CN1251758C (pl)
AU (1) AU2001280699A1 (pl)
CA (1) CA2416821A1 (pl)
CZ (1) CZ2004266A3 (pl)
HU (1) HUP0600526A2 (pl)
IL (1) IL153942A0 (pl)
MX (1) MXPA03000547A (pl)
NO (1) NO20030295D0 (pl)
NZ (1) NZ523917A (pl)
PL (1) PL365588A1 (pl)
WO (1) WO2002007677A2 (pl)
ZA (1) ZA200300641B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ523917A (en) * 2000-07-21 2004-11-26 Teva Pharma Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
US20060223888A1 (en) * 2002-12-16 2006-10-05 Abbott Frank S Valproic acid analogues and pharmaceutical composition thereof
WO2004071424A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries, Ltd. Immediate release formulation of n-(2-propylpentanoyl)glycinamide
WO2004071421A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds
IL157751A0 (en) * 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
IL156203A0 (en) * 2003-05-29 2003-12-23 Yissum Res Dev Co Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
US20060004098A1 (en) 2003-07-28 2006-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds useful for treating neurological disorders
WO2005053703A1 (en) * 2003-12-02 2005-06-16 Leslie James Sheldon Combination therapy for dementia, depression and apathy
WO2006012603A2 (en) * 2004-07-22 2006-02-02 Nps Pharmaceuticals, Inc. Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
EP1928807A4 (en) * 2005-09-02 2011-05-04 Picobella Llc ONCOGENIC REGULATORS RNA FOR DIAGNOSIS AND THERAPY
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
CN111733231A (zh) 2014-02-05 2020-10-02 耶达研究及发展有限公司 用于治疗和诊断的微rna和包含所述微rna的组合物
US11571410B2 (en) * 2016-12-14 2023-02-07 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
IL282188A (en) 2021-04-08 2022-11-01 Yeda Res & Dev Combined use of ketamine and bretigabine for the treatment of psychiatric disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU988188A3 (ru) 1973-12-14 1983-01-07 Эсакмадьяросаги Ведьимювек (Инопредприятие) Способ получени N,N-дизамещенных амидов карбоновых кислот
DE3010599A1 (de) 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung
US4301176A (en) * 1980-08-18 1981-11-17 Warner-Lambert Company Method of administering calcium valproate
FR2489319A1 (fr) 1980-08-27 1982-03-05 Clin Midy Derives de l'acide amino-4 butyrique et les medicaments, actifs notamment sur le systeme nerveux central, en contenant
BE885303A (fr) 1980-09-19 1981-03-19 Continental Pharma Glycinamides
LU83729A1 (fr) * 1981-11-04 1983-09-01 Galephar Sels d'acide valproique,leur preparation et leur utilisation
DK373383A (da) 1982-08-20 1984-02-21 Midit Fremgangsmaade til fremstilling af omega-aminosyrederivater
US4913906B1 (en) 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
IT1190133B (it) 1986-06-19 1988-02-10 Chiesi Farma Spa Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
ATE88631T1 (de) 1986-09-17 1993-05-15 Clintec Nutrition Co Zusatznahrung bzw. therapie fuer personen mit risiko oder in behandlung fuer arteriosklerotische vaskulaere, kardiovaskulaere und/oder thrombotische erkrankungen.
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
EP0921802A4 (en) 1996-03-25 2002-05-08 Lilly Co Eli METHODS FOR TREATING PAIN
IL121268A0 (en) 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
IL140415A0 (en) 1998-06-22 2002-02-10 American Biogenetic Sciences The use of valproic acid analog for the treatment and prevention of migraine and affective illness
NZ523917A (en) * 2000-07-21 2004-11-26 Teva Pharma Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder

Also Published As

Publication number Publication date
CZ2004266A3 (cs) 2005-02-16
IL153942A0 (en) 2003-07-31
CN1251758C (zh) 2006-04-19
WO2002007677A3 (en) 2002-05-30
EP1303289A4 (en) 2009-08-05
US6555585B2 (en) 2003-04-29
NO20030295L (no) 2003-01-20
WO2002007677A2 (en) 2002-01-31
EP1303289A2 (en) 2003-04-23
MXPA03000547A (es) 2004-04-05
KR100843703B1 (ko) 2008-07-04
CN1446097A (zh) 2003-10-01
NZ523917A (en) 2004-11-26
US20020103237A1 (en) 2002-08-01
AU2001280699A1 (en) 2002-02-05
CA2416821A1 (en) 2002-01-31
HUP0600526A2 (en) 2006-11-28
ZA200300641B (en) 2004-01-26
JP2004520263A (ja) 2004-07-08
US20030212142A1 (en) 2003-11-13
NO20030295D0 (no) 2003-01-20
KR20030036610A (ko) 2003-05-09

Similar Documents

Publication Publication Date Title
PL361849A1 (pl) Pochodne karboksyamidu oraz ich zastosowanie w terapii chorób zakrzepowo-zatorowych i nowotworów
IL153942A0 (en) Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
HUP0104425A3 (en) Anthranilic acid amides and the use thereof for the treatment of angiogenesis
IL149896A0 (en) Substituted oxazolidinones and their use in the field of blood coagulation
IL151946A0 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
IL151128A0 (en) Optically-active nanoparticles for use in therapeutic and diagnostic methods
HUP0101854A3 (en) The use of fumaric acid derivatives in transplant medicine
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
IL150260A0 (en) Propionic acid derivatives and their use in the treatment of diabetes and obesity
HUP0103842A3 (en) Method for the treatment of mania and bipolar disorder
HUP0102781A3 (en) Vitamin e and esters thereof for use in the topical treatment of mucosal pathologies
AP2002002393A0 (en) Naphthoquinone derivatives and their use in the treatment and control of tuberculosis
IL156139A0 (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
EP1709960A3 (en) Use of alkanoic acid-containing compositions for straightening hair
AU2001253886A1 (en) Methylxanthines in the diagnosis and treatment of autistic disorder
SI1466604T1 (sl) Novi derivati izokinolina, postopek za pripravo in uporabo le-teh za zdravljenje motenj melatoninergicnega sistema
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias
HK1055253A (en) Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
GB9922710D0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis
EP1150669A4 (en) FORMULATIONS ON L-ARGININE BASE FOR DISEASE TREATMENT AND USE THEREOF
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
GB0229366D0 (en) Improvements in and relating to methods and apparatus for the application of honey to wounds
IL154633A0 (en) Substituted phenylcyclohexane carboxylic acid amides and the use thereof
HUP0202114A3 (en) Use of benzoic acid substituted benzopyrans in medicines useful for the treatment of atherosclerosis and the medicines
IL143795A0 (en) Use of 3-isoxazolidinones and hydroxylamic acids for the treatment of infections

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)